Curtana Pharmaceuticals

Curtana Pharmaceuticals, a biotechnology company focused on improving outcomes for brain cancer patients, is proud to announce the publication of two pioneering studies in Nature Communications.

Curtana Pharmaceuticals, a privately-held, preclinical stage biopharmaceutical company, is proud to partner with the National Brain Tumor Society (NBTS) to shine a light on glioblastoma (GBM), the most common, treatment-resistant, and deadliest type of...

Curtana Pharmaceuticals, a privately-held, preclinical stage biopharmaceutical company, today announced that it has signed an agreement with Catalent to support tablet formulation and manufacturing of Curtana's CT-179, a drug therapy for the treatment of.

Data Presented in Oral Presentation at the SNO 6th Biennial Pediatric Neuro-Oncology Research Conference

Curtana Pharmaceuticals, a privately-held, preclinical stage biopharmaceutical company, today announced that the Food and Drug Administration (FDA) has granted Rare Pediatric Disease (RPD) designation to CT-179, the company's lead Olig2 inhibitor, for...

Curtana Pharmaceuticals, a privately-held, preclinical-stage biopharmaceutical company, today announced that it has completed a pre-investigational new drug (IND) meeting with the U.S. Food and Drug Administration (FDA).

Curtana Pharmaceuticals, a privately-held, preclinical stage biopharmaceutical company, today announced that the Food and Drug Administration (FDA) has granted orphan drug designation to CT-179, the company's lead Olig2 inhibitor for the treatment of...